α1アンチトリプシン欠乏症市場 - 世界の産業規模、シェア、動向、機会、予測：製品別、投与経路別、流通チャネル別、地域別、競合別、2020年～2030年

世界のα1アンチトリプシン欠乏症市場は、2024年に22億4,000万米ドルと評価され、2030年には35億3,000万米ドルに達すると予測され、予測期間中にCAGR 7.82％で成長する見込みです。

α1アンチトリプシン欠乏症は、肺と肝臓に影響を及ぼすまれな遺伝性疾患です。α-1アンチトリプシンタンパク質の欠乏によって引き起こされ、肺や肝臓の疾患を発症するリスクが高くなります。α1アンチトリプシン欠乏症はまれな疾患と考えられているが、患者のQOLやヘルスケアシステムに与える影響は大きいです。研究が進み、認知度が高まるにつれ、α1アンチトリプシン欠乏症市場は変貌を遂げ、課題と機会の両方を提供しています。α-1抗トリプシンは肝臓で産生されるタンパク質で、炎症時に放出される酵素によるダメージから肺を守るために重要な役割を果たしています。α1アンチトリプシン欠乏症を持つ患者では、遺伝子変異により、血液中に放出されずに肝臓に蓄積されるミスフォールドタンパク質が産生されます。この欠乏により、慢性閉塞性肺疾患（COPD）のような肺疾患や肝硬変のような肝疾患にかかりやすくなります。

α1アンチトリプシン欠乏症市場は、稀な疾患であるため比較的小さいです。しかし、研究者、製薬会社、ヘルスケアプロバイダーから注目を集めています。同市場の特徴は、診断、治療、療法を専門とする少数の主要企業が存在することです。これらの企業は、根本的な欠陥に対処し、関連する合併症を管理することを目的とした治療法の開発に注力しています。バイオテクノロジー、ゲノミクス、個別化医療の開発により、α1アンチトリプシン欠乏症に対するより的を絞った効果的な治療法の開発が可能になりました。これらの技術革新は、治療アプローチに革命をもたらし、患者の転帰を改善し、生活の質を向上させる可能性を秘めています。政府のイニシアチブと研究資金の増加は、世界のα1アンチトリプシン欠乏症市場の成長を促進する上で極めて重要な役割を果たしています。α1アンチトリプシン欠乏症のような希少疾患に対する認識が高まるにつれ、政府や規制機関はそのような疾患の研究、診断、治療開発を支援する政策やプログラムを導入しています。研究プロジェクト、臨床試験、患者支援プログラムへの資金提供は、製薬企業や研究者の注目を集め、この分野の進歩の加速につながっています。

主な市場促進要因

患者数の増加

主な市場課題

過小診断と誤診

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のα1アンチトリプシン欠乏症市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（α1プロテイナーゼ阻害剤、気管支拡張剤、コルチコステロイド、酸素療法）
  • 投与経路（注射、経口、吸入）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 製品別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第6章 北米のα1アンチトリプシン欠乏症市場展望

• 市場規模・予測
• 市場シェア・予測
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のα1アンチトリプシン欠乏症市場展望

• 市場規模・予測
• 市場シェア・予測
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のα1アンチトリプシン欠乏症市場展望

• 市場規模・予測
• 市場シェア・予測
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のα1アンチトリプシン欠乏症市場展望

• 市場規模・予測
• 市場シェア・予測
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのα1アンチトリプシン欠乏症市場展望

• 市場規模・予測
• 市場シェア・予測
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 競合情勢

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols S.A.
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

第14章 戦略的提言

第15章 調査会社について・免責事項

The global Alpha-1 Antitrypsin Deficiency Disease Market was valued at USD 2.24 billion in 2024 and is expected to reach USD 3.53 billion by 2030, growing at a CAGR of 7.82% during the forecast period. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency in the alpha-1 antitrypsin protein, which leads to a higher risk of developing lung and liver diseases. While Alpha-1 Antitrypsin Deficiency Disease is considered a rare disease, its impact on patients' quality of life and healthcare systems is significant. As research advances and awareness grows, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing transformations, offering both challenges and opportunities. Alpha-1 antitrypsin is a protein produced by the liver that plays a crucial role in protecting the lungs from damage caused by enzymes released during inflammation. In individuals with Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to the production of a misfolded protein that accumulates in the liver rather than being released into the bloodstream. This deficiency results in a higher susceptibility to lung diseases like chronic obstructive pulmonary disease (COPD) and liver diseases like cirrhosis.

The Alpha-1 Antitrypsin Deficiency Disease market is relatively small due to the rare nature of the disease. However, it is gaining attention from researchers, pharmaceutical companies, and healthcare providers. The market is characterized by a few key players specializing in diagnostics, treatments, and therapies. These companies focus on developing therapies that aim to address the underlying deficiency and manage associated complications. Advancements in biotechnology, genomics, and personalized medicine have enabled the development of more targeted and effective therapies for Alpha-1 Antitrypsin Deficiency Disease. These innovations have the potential to revolutionize treatment approaches, leading to better patient outcomes and improved quality of life. Government initiatives and increased research funding have played a pivotal role in driving the growth of the global Alpha-1 Antitrypsin Deficiency Disease market. As awareness about rare diseases like Alpha-1 Antitrypsin Deficiency Disease increases, governments and regulatory bodies are introducing policies and programs to support research, diagnosis, and treatment development for such conditions. Funding for research projects, clinical trials, and patient support programs have attracted the attention of pharmaceutical companies and researchers, leading to accelerated advancements in the field.

Key Market Drivers

Growing Patient Population

Alpha-1 Antitrypsin Deficiency (AATD) is a rare but serious genetic disorder that impairs lung and liver function, primarily due to insufficient levels of the alpha-1 antitrypsin protein. Though historically underdiagnosed, awareness surrounding AATD is steadily increasing. According to the Alpha-1 Foundation, it is estimated that 1 in 2,500 individuals in the United States may have the condition, but only a fraction have been properly diagnosed. This growing recognition is leading to a larger identified patient pool, highlighting the urgent need for improved diagnostic infrastructure and targeted therapies to manage and treat the condition effectively.

Misdiagnosis remains a significant hurdle in the clinical journey of many AATD patients. Because symptoms such as shortness of breath and wheezing overlap with more common conditions like asthma or chronic obstructive pulmonary disease (COPD), proper diagnosis is often delayed. However, with the rollout of improved diagnostic tools and broader genetic testing programs, correct identification is becoming more feasible. A 2023 study indicated that over 60% of newly confirmed AATD cases were initially misdiagnosed, underscoring the critical importance of awareness campaigns and early screening initiatives in catching the disease sooner and enabling timely treatment interventions.

As the pool of diagnosed patients expands, so does the interest from pharmaceutical companies and researchers to develop targeted treatments. Enzyme replacement therapies (ERTs), which replenish the deficient alpha-1 antitrypsin protein, have become a cornerstone in managing AATD. These therapies help reduce lung inflammation and preserve respiratory function. At the same time, advancements in gene therapy and RNA-based treatments are providing hope for long-term or even curative solutions. The clinical pipeline is expanding rapidly, with a number of therapies in various stages of development, targeting both symptomatic relief and genetic correction.

The availability of multiple therapeutic options is not only enhancing patient care but also creating new opportunities in the healthcare market. This is especially true as physicians are becoming more equipped to tailor treatments to the severity and progression of the disease. Increasing participation in patient registries and real-world evidence collection are further contributing to a deeper understanding of AATD and enabling personalized medicine approaches. As more individuals are diagnosed and gain access to effective care, the growing patient population will continue to be a central driver in the advancement of the Alpha-1 Antitrypsin Deficiency Disease treatment landscape.

Key Market Challenges

Under diagnosis and Misdiagnosis

One of the most pressing challenges in the Alpha-1 Antitrypsin Deficiency (AATD) market is the high rate of underdiagnosis. Due to the rarity of the condition and low awareness among both patients and primary care providers, AATD often goes undetected for years. Many individuals remain asymptomatic until the disease has significantly progressed, making early intervention difficult. Even when symptoms appear such as shortness of breath or recurrent respiratory infections-they are frequently attributed to more common conditions like asthma or chronic obstructive pulmonary disease (COPD). This diagnostic delay not only worsens patient outcomes but also limits the window of opportunity for implementing effective treatments and managing disease progression proactively.

Misdiagnosis compounds the challenge, as individuals with AATD are often treated incorrectly for unrelated respiratory or liver conditions. These inappropriate treatments can lead to ineffective care, increased healthcare costs, and a delay in addressing the root genetic cause of the symptoms. For example, corticosteroids may be prescribed under the assumption of asthma, when in fact, AATD-related lung damage requires enzyme replacement or targeted therapy. Moreover, many clinicians lack familiarity with the specific diagnostic tests needed such as serum AAT levels and genetic testing-leading to oversight in patient evaluation. This systemic issue highlights the need for increased physician education, standardized screening protocols, and public awareness campaigns to ensure timely, accurate diagnosis and improve long-term patient care.

Key Market Trends

Technological Advancements

Technological strides in genetic screening have enabled early detection of Alpha-1 Antitrypsin Deficiency Disease. Genetic tests can identify specific mutations associated with the deficiency, allowing healthcare providers to diagnose individuals even before symptoms manifest. This proactive approach empowers patients to make informed decisions about their health and lifestyle, potentially mitigating the severity of complications. Further, the advent of precision medicine, which tailors treatment plans based on an individual's genetic makeup, is revolutionizing Alpha-1 Antitrypsin Deficiency Disease management. With insights gleaned from genetic testing, medical professionals can design personalized interventions, optimizing treatment efficacy and minimizing adverse effects. The emergence of gene therapy and gene editing technologies is creating exciting avenues for treating genetic disorders like Alpha-1 Antitrypsin Deficiency Disease. Researchers are exploring ways to replace or correct the mutated gene responsible for Alpha-1 Antitrypsin Deficiency Disease, potentially restoring normal protein production. These innovative approaches hold the promise of not just managing the symptoms but addressing the root cause of the condition. Telemedicine has become an essential tool in managing chronic diseases. Patients with Alpha-1 Antitrypsin Deficiency Disease can now access remote consultations with specialists, receive real-time guidance, and monitor their health using wearable devices. This facilitates regular check-ins and timely interventions, ultimately enhancing the overall quality of care. As the technological landscape continues to evolve, the prospects for individuals with Alpha-1 Antitrypsin Deficiency are looking increasingly optimistic. Innovative therapies, precise diagnostics, and personalized treatment plans are reshaping the Alpha-1 Antitrypsin Deficiency Disease landscape, offering renewed hope to patients and their families. However, challenges such as ethical considerations, accessibility, and cost-effectiveness must also be addressed to ensure that the benefits of these technological advancements are equitably distributed. The application of big data analytics and artificial intelligence (AI) in medical research has expedited the identification of potential drug candidates. AI algorithms can analyze massive datasets to pinpoint molecules that could modulate AAT production or function, expediting the drug discovery process.

Key Market Players

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols S.A.
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

Report Scope:

In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

• Alpha-1 Proteinase Inhibitor
• Bronchodilato
• Corticosteroid
• Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

• Injection
• Oral
• Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

• Hospitals Pharmacy
• Retail Pharmacies
• Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
  • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
  • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
    • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Product
        • 6.2.4.1.2.2. By Route of Administration
        • 6.2.4.1.2.3. By Distribution Channel
    • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Product
        • 6.2.4.2.2.2. By Route of Administration
        • 6.2.4.2.2.3. By Distribution Channel
    • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Product
        • 6.2.4.3.2.2. By Route of Administration
        • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
    • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Route of Administration
        • 7.2.4.1.2.3. By Distribution Channel
    • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Route of Administration
        • 7.2.4.2.2.3. By Distribution Channel
    • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Route of Administration
        • 7.2.4.3.2.3. By Distribution Channel
    • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Route of Administration
        • 7.2.4.4.2.3. By Distribution Channel
    • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Route of Administration
        • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Product
        • 8.2.4.1.2.2. By Route of Administration
        • 8.2.4.1.2.3. By Distribution Channel
    • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Product
        • 8.2.4.2.2.2. By Route of Administration
        • 8.2.4.2.2.3. By Distribution Channel
    • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Product
        • 8.2.4.3.2.2. By Route of Administration
        • 8.2.4.3.2.3. By Distribution Channel
    • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Product
        • 8.2.4.4.2.2. By Route of Administration
        • 8.2.4.4.2.3. By Distribution Channel
    • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Product
        • 8.2.4.5.2.2. By Route of Administration
        • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Route of Administration
        • 9.2.4.1.2.3. By Distribution Channel
    • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Route of Administration
        • 9.2.4.2.2.3. By Distribution Channel
    • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Route of Administration
        • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Product
        • 10.2.4.1.2.2. By Route of Administration
        • 10.2.4.1.2.3. By Distribution Channel
    • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Product
        • 10.2.4.2.2.2. By Route of Administration
        • 10.2.4.2.2.3. By Distribution Channel
    • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Product
        • 10.2.4.3.2.2. By Route of Administration
        • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Shire plc
• 13.2. GlaxoSmithKline plc
• 13.3. CSL Behring
• 13.4. AstraZeneca Plc.
• 13.5. Grifols S.A.
• 13.6. Teva Pharmaceutical Industries
• 13.7. Boehringer Ingelheim International GmbH
• 13.8. Kamada Pharmaceuticals
• 13.9. Pfizer Inc.
• 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer